TY - JOUR U1 - Wissenschaftlicher Artikel A1 - Fneish, Firas A1 - Schaarschmidt, Frank A1 - Fortwengel, Gerhard T1 - Improving Risk Assessment in Clinical Trials: Toward a Systematic Risk-Based Monitoring Approach JF - Current Therapeutic Research N2 - Regulatory authorities have encouraged the usage of a risk-based monitoring (RBM) system in clinical trials before trial initiation for detection of potential risks and inclusion of a mitigation plan in the monitoring strategy. Several RBM tools were developed after the International Council for Harmonization gave sponsors the flexibility to initiate an approach to enhance quality management in a clinical trial. However, various studies have demonstrated the need for improvement of the available RBM tools as each does not provide a comprehensive overview of the characteristics, focus, and application. This research lays out a rationale for a risk methodology assessment (RMA) within the RBM system. The core purpose of RMA is to deliver a scientifically based evaluation and decision of any potential risk in a clinical trial. Thereby, a monitoring plan can be developed to elude prior identified risk outcome. To demonstrate RMA’s theoretical approach in practice, a Shiny web application (R Foundation for Statistical Computing) was designed to describe the assessment process of risk analysis and visualization tools that eventually aid in focusing monitoring activities. RMA focuses on the identification of an individual risk and visualizes its weight on the trial. The scoring algorithm of the presented approach computes the assessment of the individual risk in a radar plot and computes the overall score of the trial. Moreover, RMA’s novelty lies in its ability to decrease biased decision making during risk assessment by categorizing risk influence and detectability; a characteristic pivotal to serve RBM in assessing risks, and in contributing to a better understanding in the monitoring technique necessary for developing a functional monitoring plan. Future research should focus on validating the power of RMAs to demonstrate its efficiency. This would facilitate the process of characterizing the strengths and weaknesses of RMA in practice. KW - ICH-GCP KW - Mitigation plan KW - Risk-based monitoring KW - Risk methodology assessment KW - Klinisches Experiment KW - Risikoanalyse KW - Entscheidungsfindung Y1 - 2021 UN - https://nbn-resolving.org/urn:nbn:de:bsz:960-opus4-20938 SN - 0011-393X SS - 0011-393X U6 - https://doi.org/10.25968/opus-2093 DO - https://doi.org/10.25968/opus-2093 VL - 95 SP - 7 S1 - 7 ER -